Acrivon Therapeutics Azioni (NASDAQ: ACRV)

Ultime notizie per Acrivon Therapeutics (NASDAQ:ACRV) Azioni

Acrivon Therapeutics

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics Inc

DA Davidson analyst Linda Bolton Weiser upgrades Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from Neutral to Buy and raises the price target from $160 to $209.

News

Upgrades

Price Target

Analyst Ratings

DA Davidson Upgrades Procter & Gamble to Buy, Raises Price Target to $209

Canaccord Genuity analyst Edward Nash initiates coverage on Apogee Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) with a Buy rating and announces Price Target of $89.

Initiation

APGE

Canaccord Genuity Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $89

Wedbush analyst Daniel Ives upgrades Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Outperform and announces $190 price target.

SNOW

Wedbush Upgrades Snowflake to Outperform, Announces $190 Price Target

Old National Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) ("Old National") and Bremer Financial Corporation ("BFC" or "Bremer") jointly announced today that they entered into a definitive merger agreement. Founded in 1943, BFC is the bank holding company for Bremer Bank.
As of September 30, 2024, Bremer had $16.2 billion in total assets, $11.5 billion in total loans, and $13.2 billion in deposits. After the partnership is completed, Old National will become the third-largest bank in the Twin Cities. In addition, the partnership expands Old National's reach into several other vibrant markets throughout Minnesota, North Dakota and Wisconsin. Once combined, the new organization would have over $70 billion in assets (based on September 30, 2024 asset figures), a significantly larger footprint, and offer additional banking capabilities and enhanced resources to serve customers.
"This partnership represents an outstanding fit between two highly compatible, relationship- and community-focused banks," said Old National Chairman and CEO Jim Ryan. "When you look at what has made Bremer Bank a leading institution since 1943, what you quickly find are the same strategic priorities and cultural principles that have guided Old National's success for 190 years: a strong deposit franchise, a diversified loan portfolio accentuated by exceptional credit quality, and a passion for investing in and strengthening communities. I am incredibly confident that, through this partnership, Bremer and Old National will be even better together."
"For more than 80 years, we've been honored to carry out the legacy of our founder, Otto Bremer," said Jeanne Crain, President and CEO of Bremer. "When our majority shareholder, the Otto Bremer Trust, reaffirmed its interest in selling Bremer Bank, we appreciated the opportunity to identify a partner through a collaborative process to ensure the best possible outcome for our customers, employees, and our communities. With Old National, we have confidence we found a great fit."
The Otto Bremer Trust The Otto Bremer Trust (the "Trust") is a private charitable trust based in St. Paul, Minnesota. It currently holds a majority ownership stake in Bremer. Established in 1944, the Trust works to combine finance and philanthropy in service of the community. Since its inception, the Trust has made more than $1.1 billion in grants and program-related investments to more than 4,200 organizations.
Upon closing of this transaction, the Trust will have an approximate 11% ownership stake in Old National and a Trustee of the Otto Bremer Trust will join the Old National Board of Directors.
The Otto Bremer Trust commented: "All of us at the Otto Bremer Trust are excited that the Bremer Bank legacy of investing in people, places and opportunities continues with one of the most community-minded banks in the nation. This partnership expands the scope of what can be accomplished for and within our communities – civically, socially and economically."
The partnership transaction includes 70 total banking centers in Minnesota, North Dakota and Wisconsin
48 branches in Minnesota, including:
<ul>
<li>18 locations in the Twin Cities region</li>
<li>5 locations in the Rochester region</li>
<li>7 locations in the Alexandria region</li>
<li>4 locations in the St. Cloud region</li>
</ul>
14 branches in North Dakota, including:
<ul>
<li>6 locations in the Grand Forks region</li>
<li>7 locations in the Fargo region</li>
</ul>
8 branches in Wisconsin, including:
<ul>
<li>1 location in Appleton</li>
<li>1 location in Eau Claire</li>
</ul>
Under the terms of the definitive merger agreement, each outstanding share of Bremer common stock will be converted into the right to receive 4.182 shares of Old National common stock plus $26.22 in cash, valuing the transaction at approximately $1,401 million, or $116.76 per share, based on Old National's closing stock price on November 22, 2024. The definitive merger agreement has been unanimously approved by the Board of Directors of Bremer and Old National. The transaction is subject to customary closing conditions and regulatory approvals, including the approval of Bremer shareholders. The transaction is anticipated to close in the middle of 2025.
&nbsp;

Old National Acquires Bremer Bank in $1.4B Deal, Expanding Midwest Footprint

JMP Securities analyst Aaron Kimson downgrades Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) from Market Outperform to Market Perform.

Downgrades

EXFY

JMP Securities Downgrades Expensify to Market Perform

Meents most recently served as President of Intermodal &amp; Transportation Solutions, Chief Marketing Officer, and in various other operational, account management, pricing, sales and marketing roles since joining the Company in 2009.
Brian Alexander, previously the Company's Chief Operating Officer, will assume the role of Chief Marketing Officer.

Management

HUBG

Hub Group Board Appoints Brian Meents As Executive Vice President And COO - Filing

Old National Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) ("Old National") today announced the pricing of an underwritten public offering of 19,047,619 shares of its common stock, no par value (the "Common Stock"), at a public offering price of $21.00 per share (before underwriting discounts and commissions), for an aggregate offering amount of $400 million. The approximate net proceeds of the offering will be $384 million (before offering expenses, assuming the underwriters do not exercise their option to purchase additional shares and assuming full physical settlement of the forward sale agreement at the initial forward price) in connection with the forward sale agreement described below.

Offerings

Old National Bancorp To Raise $400M Via Secondary Stock Offering Of 19M Shares At $21/Share

In a remarkable turn of events, MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) saw its shares jump by 5.93% in pre-market trading on Monday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This surge comes on the heels of co-founder Michael Saylor&#8216;s announcement that the company is generating $500 million daily as Bitcoin edges closer to the $100,000 mark.
What Happened: At the time of reporting, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was valued at $98,273.58. The cryptocurrency&#8217;s rise has significantly impacted MicroStrategy&#8217;s performance, as the company has heavily invested in Bitcoin.
On the same day,&nbsp;Canaccord Genuity&nbsp;reaffirmed its Buy rating for MicroStrategy&#8217;s stock, elevating its price target from $300.00 to $510.00. The firm commended MicroStrategy&#8217;s novel strategy in assessing&nbsp;value creation through a new&nbsp;key performance indicator centered&nbsp;on Bitcoin accretion per share&nbsp;and Bitcoin yield.
See Also: <a href="https://www.benzinga.com/general/social-media/24/11/42154487/robert-kiyosaki-trump-will-make-america-richer-again-by-being-the-first-bitcoin-president?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Robert Kiyosaki: &#8216;Trump Will Make America Richer Again By Being The First Bitcoin President&#8217;</a>
Why It Matters: Saylor recently revealed that <a href="https://www.benzinga.com/24/11/42151809/michael-saylor-reveals-microstrategy-is-making-500m-a-day-with-bitcoin-may-very-well-be-the-most-profitable-company-in-the-us-growing-the-fastest-right-now">MicroStrategy is minting $500 million a day</a> as Bitcoin approaches $100,000 for the first time. Saylor highlighted the company&#8217;s massive gains, noting that their Bitcoin holdings appreciated by $5.4 billion over two weeks. This underscores the significant impact of Bitcoin&#8217;s value on MicroStrategy&#8217;s financial health.
However, not everyone is convinced of MicroStrategy&#8217;s valuation.&nbsp;<a href="https://www.benzinga.com/24/11/42156261/are-microstrategys-shares-worth-only-105-investment-adviser-gary-black-weighs-in">Investment adviser Gary Black</a>&nbsp;questioned the company&#8217;s stock price, suggesting it might be overpriced. Black pointed out that while MicroStrategy&#8217;s Bitcoin holdings were valued at $31.2 billion, the company&#8217;s market value was $106 billion, raising concerns about its equity value.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42146459/bitcoin-on-brink-of-breaking-100000-dogecoin-up-ethereum-down-crypto-community-holds-its-breath-as-btc-guns-for-milestone?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin &#8216;On Brink Of Breaking $100,000,&#8217; Dogecoin Up, Ethereum Down: Crypto Community Holds Its Breath As BTC Guns For Milestone</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Pre-Market Outlook

Markets

General

$BTC

MSTR

MicroStrategy Shares Rise In Monday Pre-Market As Michael Saylor Reveals MSTR Generating $500M Daily Amid Bitcoin's Surge

Contracts

Solidion Technology Has Signed A Strategic Memorandum Of Understanding With Giga Solar Materials, A Materials Manufacturer Out Of Taiwan, To Accelerate The Production Of Silicon Oxide Anode Materials In US

TD Cowen analyst Joseph Thome initiates coverage on Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy rating.

VRDN

TD Cowen Initiates Coverage On Viridian Therapeutics with Buy Rating

DURECT Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET&#xAE; line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
<a href="https://mma.prnewswire.com/media/81466/DURECT_LOGO_2023.html">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (<a href="http://www.durect.com/">www.durect.com</a>) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer."&gt;
Under the terms of the agreement, LIC paid&nbsp;DURECT&nbsp;$17.5 million in exchange for certain assets and liabilities associated with&nbsp;the ALZET&nbsp;product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.&nbsp;

Asset Sales

DRRX

DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations

TD Cowen analyst Kevin Kopelman downgrades Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) from Buy to Sell and raises the price target from $12 to $14.

DESP

TD Cowen Downgrades Despegar.com to Sell, Raises Price Target to $14

<a href="https://www.reuters.com/business/energy/trump-prepares-wide-ranging-energy-plan-boost-gas-exports-oil-drilling-sources-2024-11-25/" title="https://www.reuters.com/business/energy/trump-prepares-wide-ranging-energy-plan-boost-gas-exports-oil-drilling-sources-2024-11-25/">https://www.reuters.com/business/energy/trump-prepares-wide-ranging-energy-plan-boost-gas-exports-oil-drilling-sources-2024-11-25/</a>

Commodities

Reuters Reported President Elect Trump Plans To Repeal Biden's Clean Power Plan, Boost Natural Gas, Lift Pause On New LNG Export Permits, And Expedite Pending Approvals

Earnings

Super Hi International Q3 EPS $0.06 Misses $0.21 Estimate, Sales $198.62M Miss $227.49M Estimate

Tractors and Farm Equipment Limited, is the largest shareholder of AGCO with a 16.3% long-term strategic ownership interest in the Company.

AGCO

AGCO Shareholder TAFE Urges To Separate Board Chair And CEO Roles At 2025 Annual Meeting

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) investors have no shortage of reasons to continue bidding up NVDA stock. Primarily, the semiconductor stalwart — known for its advanced graphics processors that undergird artificial-intelligence-based platforms and applications — recently posted financial results for the third quarter that<a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights"> handily beat expectations</a>.
Management disclosed earnings per share of 81 cents, outpacing Wall Street's expectation calling for 75 cents. Notably, the tech firm beat its bottom-line target for eight straight quarters. On the top line, Nvidia rang up sales of $35.1 billion, up a whopping 94% on a year-over-year basis. This tally also exceeded the consensus view of $33.12 billion.
According to Wedbush Securities Managing Director Dan Ives, the chipmaker's results were a "jaw-dropper." Further, the market expert<a href="https://www.benzinga.com/markets/equities/24/11/42102642/nvidia-delivered-jaw-dropping-q3-earnings-says-dan-ives-this-is-the-fourth-revolution-playing-out-in-front-of-our-eyes"> emphasized the transformative potential</a> of the underlying AI innovation. "This is the fourth revolution playing out in front of our eyes," Ives told CNN.
Not to be left outdone, CNBC personality Jim Cramer<a href="https://www.benzinga.com/news/global/24/11/42129914/jim-cramer-doubles-down-on-nvidia-demand-is-accelerating-as-ai-customers-have-no-choice-but-to-buy-its-chips"> pounded the table</a> on NVDA stock. "The demand is accelerating because the payoff is so great," the analyst remarked, mentioning Nvidia CEO Jensen Huang's claim that customers earn five dollars for every dollar invested in Nvidia chips.
Still, not every indicator is so glaringly positive for NVDA stock. Interestingly, when the tech giant released its Q3 report last week, the initial response wasn't exactly encouraging. Instead,<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42107846/nvidia-slides-during-thursday-pre-market-despite-beating-q3-estimates-even-outstanding-isnt-enough-for-some-investors"> shares slipped</a> during the pre-market hours of the Nov. 21 session. As the company continues to bring home the goods, expectations also rise, possibly presenting challenges.
Conspicuously, on Friday, NVDA stock dropped more than 3%. During the session,<a href="https://fintel.io/sof/us/nvda"> options flow data</a> — which focuses exclusively on big block transactions likely placed by institutional or professional investors — saw a significant influx of transactions with apparently bearish implications: both long puts and short calls. This dynamic raises suspicions that some market participants are becoming skeptical about Nvidia.
The Direxion ETFs: For investors that enjoy approaching the equities arena from a tactical view, financial services provider Direxion offers two directionally opposite exchange-traded funds. Optimists in the AI narrative may consider Direxion Daily NVDA Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDU#NASDAQ">NVDU</a>), which seeks daily investment results of 200% of the performance of NVDA stock.
Those who are pessimistic about Nvidia's rally sustaining itself may consider Direxion Daily NVDA Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDD#NASDAQ">NVDD</a>). This ETF attempts to replicate 100% of the inverse performance of NVDA stock. To be clear, both leveraged and inverse ETFs are designed to be held for periods lasting no longer than one day. Exposure beyond this recommended period may lead to valuation erosion due to the daily compounding of leverage.
The NVDU ETF: Since the start of the year, the NVDU ETF returned traders just over 359%, highlighting the blistering results that Nvidia posted. Still, some kinks in the armor raise questions.
<ul>
<li>In the trailing month, NVDU gained just over 1%, potentially revealing investor hesitation regarding the overall AI message.</li>
<li>The leveraged bull fund is comfortably above its 200-day moving average. However, the price action is narrowing toward its 50 DMA, warranting vigilance.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeQdd2BM4qeTSFWYs3aQVUBd2kOe6jRoNa2rxAZ0VW7ro2wiFm2UkW30cZJozR7WbVJO8eSNwN5GRbu8-bm4oB-lFyiiHk0g0azkjggkwwjhYDMJ555D9xNW8eQbhggQgCIlw4_IQ?key=DULWMCTnciRpWBUBkeoLDsyd" alt="" /></figure>
The NVDD ETF: Unsurprisingly, the NVDD ETF struggled badly this year, losing almost 73% of value since the beginning of January. However, it's possible that sentiment may be reversing.
<ul>
<li>Friday's price action brought the inverse fund level with its 20-day exponential moving average. Nvidia pessimists now have the 50 DMA within realistic striking distance.</li>
<li>It's worth noting that NVDD enjoyed a dramatic surge in volume since the middle of November, potentially reflecting a shift in market appetite for AI.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXc6n1RW4tEJZNtITFmqx3JCWlCotkhm0Y3Ode37mtzHwWoVjcNPSk84ZVkMaZnBv8lG4b_a_wY0rIAAIK573o9TUOPRzGuKjiwG9jhbeqOKBPUilcT-6N9hw4N2C5alSdDDyLehSA?key=DULWMCTnciRpWBUBkeoLDsyd" alt="" /></figure>
Featured image by <a href="https://pixabay.com/users/nanadua11-4908484/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5268574">Nana Dua</a> from <a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5268574">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

NVDA

NVDD

NVDU

Raging AI Debate Delivers Fuel For Direxion's Nvidia-Focused Funds NVDU And NVDD

Santech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) ("Santech" or the "Company") announced today that it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on November 21, 2024 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended June 30, 2024, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of the Company's American depositary shares on the Nasdaq.
Under Nasdaq's listing rules, the Company has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 20-F's due date, or until May 14, 2024, to regain compliance.
The Company is currently working with its advisers to prepare the Filing or to formulate the requisite plan to regain compliance and intends to submit such Filing or such plan to Nasdaq within the timeframe required under Nasdaq's Rules.

Government

Regulations

STEC

Santech Faces Nasdaq Non-Compliance Notice Over Delayed Filing Of Its Annual Report On Form 20-F For Year Ended June 30, 2024

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is ramping up efforts to challenge Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in the artificial intelligence (AI) chip market, worth over $100 billion. 
From a bustling engineering lab in Austin, Texas, Amazon&#8217;s engineers are pushing to market its latest AI chip, Trainium 2, as quickly as possible, Bloomberg <a href="https://www.bloomberg.com/news/features/2024-11-24/amazon-plans-to-rival-nvidia-with-its-own-ai-chips?srnd=phx-technology&amp;sref=TBDibEcD" target="_blank" rel="noreferrer noopener">reports</a>. Rami Sinno spearheads the Trainium 2 project and leads Amazon&#8217;s chip design and testing.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25032053/newplot-12.png" alt="" class="wp-image-662826" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25032053/newplot-12.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25032053/newplot-12-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42146205/gaps-growth-drivers-market-share-gains-brand-momentum-and-raised-guidance-analysts-weigh-in" rel="noreferrer noopener">Gap&#8217;s Growth Drivers: Market Share Gains, Brand Momentum, And Raised Guidance – Analysts Weigh In</a>
Despite Nvidia&#8217;s significant lead in AI hardware, Amazon&#8217;s ambitions to reduce dependency on external suppliers and deliver competitive AI solutions have gained traction.
Amazon&#8217;s latest AI chip, Trainium 2, offers improved performance with four times the computational power and three times the memory of its predecessor, per the report.
Engineers have streamlined its design by reducing internal components and improving heat management. The chip is central to Amazon&#8217;s strategy of scaling its AI capabilities and offering a cost-effective alternative to Nvidia hardware.
Prominent AI startups, including Anthropic, are adopting Amazon&#8217;s Trainium chips for their workloads. Last week, Amazon <a target="_blank" href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch" rel="noreferrer noopener">increased its funding</a> in Anthropic to $8 billion, solidifying its collaboration on AI advancements and positioning Amazon Web Services (AWS) as the startup&#8217;s primary cloud provider.
In October, Amazon signed a five-year agreement with Databricks to deliver cost-efficient <a target="_blank" href="https://www.benzinga.com/news/24/10/41337034/amazon-strikes-at-nvidias-stronghold-through-databricks-deal-cutting-ai-costs-by-40" rel="noreferrer noopener">AI-building solutions</a> to businesses.
The collaboration focuses on Amazon&#8217;s Trainium AI chips, offering a budget-friendly alternative to Nvidia&#8217;s widely used GPUs for AI customization. Databricks intends to pass on the savings from Trainium&#8217;s use to customers, challenging Nvidia&#8217;s dominance in the AI hardware market.
Amazon faces hurdles in software development, an area where Nvidia excels. Its Neuron SDK, still in its early stages, must evolve to match the ease and flexibility Nvidia offers to AI developers.
Meanwhile, Nvidia&#8217;s Blackwell chips won&#8217;t <a target="_blank" href="https://www.benzinga.com/news/24/10/41405124/whats-going-on-with-nvidia-stock-on-friday" rel="noreferrer noopener">reach the market</a> until early 2025, impacting significant clients such as AWS. Production challenges at Nvidia have forced AWS to await bulk production of Blackwell chips for its data centers. AWS Chief Matt Garman highlighted the delay during an interview on Bloomberg Television, citing Nvidia&#8217;s production adjustments.
In September, DA Davidson&#8217;s Gil Luria downgraded Microsoft Corp to Neutral, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40986921/microsofts-ai-lead-shrinks-analyst-downgrades-stock-as-amazon-and-google-close-the-" rel="noreferrer noopener">citing diminishing AI</a> and cloud leadership as key factors. Luria highlighted AWS and Alphabet Inc Google Cloud&#8217;s strides in silicon deployment, outpacing Microsoft&#8217;s Azure in data center advancements. Despite early AI gains, Luria flagged competitors like AWS and GitLab as catching up to GitHub Copilot, challenging Microsoft&#8217;s edge in innovation.
Price Action: AMZN stock closed lower by 0.64% at $197.12 on Friday.
Image via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42144915/china-unveils-global-ai-governance-committee-with-alibaba-cloud-founder-at-the-helm" target="_blank" rel="noreferrer noopener">China Unveils Global AI Governance Committee With Alibaba Cloud Founder At The Helm</a></li>
</ul>

Media

AMZN

MSFT

Amazon's AI Chip Strategy Targets Nvidia's Dominance In Data Centers

BEDU

Bright Scholar Education Q4 Adj EPADS $(0.44) Up From $(0.52) YoY, Sales $50.53M Down From $77.12M YoY

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) with a Buy and maintains $75 price target.

Reiteration

LIVN

Needham Reiterates Buy on LivaNova, Maintains $75 Price Target

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

An update from Acrivon Therapeutics, Inc. ( ($ACRV) ) is now available. Acrivon Therapeutics has initiated a Phase 1 clinical trial for ACR-2316, a...

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), wit...

Acrivon Therapeutics: Promising Innovations in WEE1/PKMYT1 Inhibition and AP3 Platform Drive Buy Rating

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), with a pri...

Acrivon Therapeutics: Buy Rating Driven by Promising Oncology Advancements and Strategic Positioning

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), retaining the price target ...

Promising Outlook for Acrivon Therapeutics: Buy Rating Affirmed on Strong ACR-368 Data and Strategic Growth Plans

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report). The associated price ta...

Promising Clinical Developments and Strong Financial Position Drive Buy Rating for Acrivon Therapeutics

TD Cowen analyst Marc Frahm has maintained their bullish stance on ACRV stock, giving a Buy rating today. Marc Frahm has given his Buy rating due t...

Acrivon Therapeutics, Inc.: Promising Advancements and Strong Buy Rating Backed by Innovative Pipeline and Solid Financial Position

Acrivon Therapeutics GAAP EPS of -$0.59

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) today and set a price target ...

Acrivon Therapeutics: Promising Pipeline and Robust Financials Underpin Buy Rating

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a price tar...

Strong Growth Outlook for Acrivon Therapeutics, Inc. Backed by Promising Pipeline and Strategic Advancements

ACRV

Press Releases

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Health Care

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Acrivon Therapeutics

Notizie

Ultime notizie per Acrivon Therapeutics (NASDAQ:ACRV) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO